VK-2735 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This VK-2735 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
5
Registered trials
6
Result records
24
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether VK-2735 can convert its Synthetic peptide profile and GIPR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | VK-2735 (query alias: VK2735) |
|---|---|
| Modality / target | Synthetic peptide; GIPR x GLP-1R; GIPR agonists, GLP-1R agonists |
| Highest global status | Phase 3 |
| Originator | Viking Therapeutics, Inc. |
| Active developers | Viking Therapeutics, Inc. |
The MCP disease footprint includes Diabetes Mellitus, Type 2, Obesity, Metabolic Dysfunction Associated Steatohepatitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07104500 | Phase 3 | Active, not recruiting | 4500 | Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment |
| NCT07104383 | Phase 3 | Active, not recruiting | 1100 | Percent change in body weight from baseline to Week 78 in body weight |
| NCT06828055 | Phase 2 | Completed | 280 | Percent (relative) change from baseline in body weight after 13 weeks of treatment |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: -; Body weight = -14.6 kg ; Body weight = -9.2 kg
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: Body weight(13-week) = -12.2 % Met; Body weight(13-week) = -11.1 % Met; Body weight(13-week) = -1.3 % Met
First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults
Phase 1/2; n=not disclosed; evaluation: Positive. Reported fields: Body weight = -8.2 % ; Body weight = -5.1 % ; Body weight = -3.5 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
VK-2735 addresses Diabetes Mellitus, Type 2, Obesity, Metabolic Dysfunction Associated Steatohepatitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 24 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GIPR x GLP-1R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-01-30 | CSPC Pharmaceutical Group Limited Enters into Strategic Collaboration and License Agreement with AstraZeneca for the Development of Innovative Long-Acting Peptide Medicines | IND Application | US$1,200.0M upfront; US$17,300.0M milestones |
| 2026-01-16 | 10亿元！众生睿创GLP-1/GIP双重激动剂授权齐鲁制药 | Phase 3 | US$28.7M upfront; US$114.8M milestones; US$143.5M stated total |
| 2026-01-08 | Alveus Therapeutics licensed ex-China rights to ALV-100 from China-based Gmax Biopharm | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination of GLP-1r/GIPR dual agonist and FGF21 compound and use”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
